Opinion|Videos|February 18, 2025
Adoption of New Treatments for BCG-Unresponsive NMIBC
Author(s)Mark D. Tyson, II, MD, MPH
A panelist discusses how the ability to administer newer non–muscle-invasive bladder cancer (NMIBC) treatments in local urology practices rather than specialized oncology centers reduces patient burden and travel requirements while suggesting that increased education and support could help more health care providers adopt these treatment options.
Advertisement
Episodes in this series
- From an operational standpoint, how important is it that these treatments can be administered by urologists locally, without the need to refer patients to oncology centers? Please discuss the overall burden on patients, systemic adverse effects, and the need to travel to specialized centers.
- What strategies would you recommend to encourage more health care practitioners to adopt newer treatment modalities for BCG-unresponsive NMIBC?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
4
Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD
5